Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1Phase 1/2 1

Status

Completed 4Withdrawn 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 2Gastrointestinal 2Gynecologic 1

Conditions

Prostatic Neoplasms 1Prostate Cancer Metastatic 1Colorectal and Ovarian Cancer Patients With Liver Metastases 1Colorectal Neoplasms 1

Interventions

Paclitaxel 490Carboplatin 436Gemcitabine 394Docetaxel 385Cisplatin 360pembrolizumab 344Bevacizumab 335Nivolumab 261Pemetrexed 243Capecitabine 221Dexamethasone 213Fluorouracil 211Rituximab 203Trastuzumab 193Cyclophosphamide 190Oxaliplatin 160Erlotinib Hydrochloride 147Ipilimumab 145atezolizumab 144Prednisone 144Cetuximab 142Irinotecan 139Leucovorin 130Doxorubicin 130Sorafenib 120Lenalidomide 119Bortezomib 118Sunitinib 107Everolimus 93130-nm albumin-bound paclitaxel 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × INDUSTRY × Abituzumab × Clear all
NCT00958477 2017-08-02

A Study to Determine the Safety, Tolerability, Pharmacokinetics and Dynamic Effects of Different Doses of the Study Drug EMD 525797 in Prostate Cancer

Merck KGaA, Darmstadt, Germany

Phase 1 Completed
26 enrolled 44 charts
Genitourinary

Prostatic Neoplasms

NCT01008475 2016-03-30

POSEIDON

Merck KGaA, Darmstadt, Germany

Phase 1/2 Completed
232 enrolled 20 charts
Gastrointestinal

Colorectal Neoplasms

NCT00848510 2015-12-14

EMD 525797 in Colorectal and Ovarian Cancer Patients With Liver Metastases

Merck KGaA, Darmstadt, Germany

Phase 1 Completed
41 enrolled 18 charts
GastrointestinalGynecologic

Colorectal and Ovarian Cancer Patients With Liver Metastases

NCT01360840 2015-12-14

PERSEUS

EMD Serono

Phase 2 Completed
180 enrolled 23 charts
Genitourinary

Prostate Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡